- Home
- RNAZ
as 07-26-2024 4:00pm EST
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 6.3M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 890.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -229.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.29 - $128.00 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TransCode Therapeutics Inc. News
RNAZ Breaking Stock News: Dive into RNAZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
TransCode Therapeutics, Inc. Announces Closing of Public Offering
GlobeNewswire
4 days ago
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
GlobeNewswire
4 days ago
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire
2 months ago
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
GlobeNewswire
2 months ago
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
GlobeNewswire
2 months ago
TransCode Therapeutics Open Letter to Shareholders
GlobeNewswire
3 months ago
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
GlobeNewswire
4 months ago
TransCode Therapeutics Reports 2023 Results; Provides Business Update
Compare RNAZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAZ TransCode Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.